{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T19:12:31Z","timestamp":1790622751998,"version":"4.1.0"},"reference-count":72,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["HHSN271201700008C"],"award-info":[{"award-number":["HHSN271201700008C"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["T32DA007027"],"award-info":[{"award-number":["T32DA007027"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007880","name":"Johns Hopkins University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007880","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.bcp.2021.114805","type":"journal-article","created":{"date-parts":[[2021,10,19]],"date-time":"2021-10-19T20:17:07Z","timestamp":1634674627000},"page":"114805","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":56,"special_numbering":"C","title":["Respiratory depressant effects of fentanyl analogs are opioid receptor-mediated"],"prefix":"10.1016","volume":"195","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3181-9580","authenticated-orcid":false,"given":"Neil B.","family":"Varshneya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6507-1166","authenticated-orcid":false,"given":"Sherif H.","family":"Hassanien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7883-924X","authenticated-orcid":false,"given":"Melissa C.","family":"Holt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David L.","family":"Stevens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan K.","family":"Layle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathon R.","family":"Bassman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna M.","family":"Iula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick M.","family":"Beardsley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.bcp.2021.114805_b0005","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1177\/2049463712438493","article-title":"Basic opioid pharmacology: an update","volume":"6","author":"Pathan","year":"2012","journal-title":"Br. J. Pain"},{"issue":"6","key":"10.1016\/j.bcp.2021.114805_b0010","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1097\/ALN.0b013e318238bba6","article-title":"Molecular mechanisms of opioid receptor-dependent signaling and behavior","volume":"115","author":"Al-Hasani","year":"2011","journal-title":"Anesthesiology"},{"key":"10.1016\/j.bcp.2021.114805_b0015","series-title":"Regional differences in the drugs most frequently involved in drug overdose deaths: United States, 2017","author":"Hedegaard","year":"2019"},{"key":"10.1016\/j.bcp.2021.114805_b0020","series-title":"Drugs most frequently involved in drug overdose deaths: United States, 2011\u20132016","author":"Hedegaard","year":"2018"},{"key":"10.1016\/j.bcp.2021.114805_b0025","series-title":"Drug overdose deaths involving fentanyl, 2011\u20132016","author":"Spencer","year":"2019"},{"key":"10.1016\/j.bcp.2021.114805_b0030","unstructured":"Drug Enforcement Administration, NFLIS Brief: Fentanyl, 2001\u20132015, NFLIS Brief: Fentanyl, 2001\u20132015 (March 2017) (2017)."},{"key":"10.1016\/j.bcp.2021.114805_b0035","unstructured":"Drug Enforcement Administration, NFLIS Brief: Fentanyl and Fentanyl-Related Substances Reported in NFLIS, 2015\u20132016, National Forensic Laboratory Information System (2017)."},{"key":"10.1016\/j.bcp.2021.114805_b0040","series-title":"NFLIS-DRUG 2019 Annual Report","author":"Drug Enforcement Administration","year":"2020"},{"issue":"5","key":"10.1016\/j.bcp.2021.114805_b0045","doi-asserted-by":"crossref","first-page":"422","DOI":"10.2165\/00003088-198308050-00004","article-title":"Clinical pharmacokinetics of fentanyl and its newer derivatives","volume":"8","author":"Mather","year":"1983","journal-title":"Clin. Pharmacokinet."},{"issue":"1","key":"10.1016\/j.bcp.2021.114805_b0050","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1213\/00000539-198501000-00010","article-title":"Anesthetic induction with fentanyl","volume":"64","author":"Bailey","year":"1985","journal-title":"Anesth. Analg."},{"issue":"4","key":"10.1016\/j.bcp.2021.114805_b0055","doi-asserted-by":"crossref","first-page":"275","DOI":"10.2165\/00003088-199631040-00004","article-title":"Clinical pharmacokinetics of alfentanil, fentanyl and sufentanil. An update","volume":"31","author":"Scholz","year":"1996","journal-title":"Clin. Pharmacokinet."},{"issue":"2","key":"10.1016\/j.bcp.2021.114805_b0060","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1097\/00000542-199902000-00034","article-title":"A review of the use of fentanyl analgesia in the management of acute pain in adults","volume":"90","author":"Peng","year":"1999","journal-title":"Anesthesiology"},{"key":"10.1016\/j.bcp.2021.114805_b0065","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.forsciint.2018.05.042","article-title":"Abuse of fentanyl: An emerging problem to face","volume":"289","author":"Kuczy\u0144ska","year":"2018","journal-title":"Forensic Sci. Int."},{"key":"10.1016\/j.bcp.2021.114805_b0070","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.neubiorev.2018.12.005","article-title":"Fentanyl: Receptor pharmacology, abuse potential, and implications for treatment","volume":"106","author":"Comer","year":"2019","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.bcp.2021.114805_b0075","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.jsat.2018.10.007","article-title":"Fentanyl exposure among patients seeking opioid treatment","volume":"96","author":"Ochalek","year":"2019","journal-title":"J. Subst. Abuse Treat."},{"issue":"1","key":"10.1016\/j.bcp.2021.114805_b0080","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/ajad.13092","article-title":"The Increasing prevalence of fentanyl: a urinalysis-based study among individuals with opioid use disorder in New York City","volume":"30","author":"Martinez","year":"2021","journal-title":"Am. J. Addict."},{"key":"10.1016\/j.bcp.2021.114805_b0085","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.jsat.2018.01.005","article-title":"Expected and actual fentanyl exposure among persons seeking opioid withdrawal management","volume":"86","author":"Kenney","year":"2018","journal-title":"J. Subst. Abuse Treat."},{"key":"10.1016\/j.bcp.2021.114805_b0090","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jsat.2017.01.004","article-title":"Characterizing fentanyl use in methadone-maintained clients","volume":"75","author":"Arfken","year":"2017","journal-title":"J. Subst. Abuse Treat."},{"issue":"16","key":"10.1016\/j.bcp.2021.114805_b0095","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1001\/jama.2020.17477","article-title":"Nonfatal opioid overdoses at an urban emergency department during the COVID-19 pandemic","volume":"324","author":"Ochalek","year":"2020","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.bcp.2021.114805_b0100","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1080\/00952990.2021.1891420","article-title":"A cross-sectional analysis of fentanyl analog exposures among living patients","volume":"47","author":"Chhabra","year":"2021","journal-title":"Am. J. Drug Alcohol Abuse"},{"issue":"7","key":"10.1016\/j.bcp.2021.114805_b0105","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1093\/jat\/27.7.499","article-title":"Fentanyl use, misuse, and abuse: a summary of 23 postmortem cases","volume":"27","author":"Kuhlman","year":"2003","journal-title":"J. Anal. Toxicol."},{"issue":"8","key":"10.1016\/j.bcp.2021.114805_b0110","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1093\/jat\/30.8.603","article-title":"Fentanyl-related deaths in Ontario, Canada: toxicological findings and circumstances of death in 112 cases (2002\u20132004)","volume":"30","author":"Martin","year":"2006","journal-title":"J. Anal. Toxicol."},{"issue":"4","key":"10.1016\/j.bcp.2021.114805_b0115","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1111\/j.1556-4029.2007.00481.x","article-title":"Fentanyl concentrations in 23 postmortem cases from the hennepin county medical examiner's office","volume":"52","author":"Thompson","year":"2007","journal-title":"J. Forensic Sci."},{"key":"10.1016\/j.bcp.2021.114805_b0120","unstructured":"Centers for Disease Control and Prevention, Multiple Cause of Death 1999-2019 on CDC WONDER Online Database, released in 2020. Data are from the Multiple Cause of Death Files, 1999-2019, as compiled from data provided by the 57 vital statistics jurisdictions through the Vital Statistics Cooperative Program., National Center for Health Statistics (2020)."},{"issue":"8","key":"10.1016\/j.bcp.2021.114805_b0125","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1002\/dta.2822","article-title":"In vitro pharmacology of fentanyl analogs at the human mu opioid receptor and their spectroscopic analysis","volume":"12","author":"Hassanien","year":"2020","journal-title":"Drug Test. Anal."},{"key":"10.1016\/j.bcp.2021.114805_b0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2020.114293","article-title":"Affinity, potency, efficacy, selectivity, and molecular modeling of substituted fentanyls at opioid receptors","volume":"182","author":"Eshleman","year":"2020","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bcp.2021.114805_b0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2020.113910","article-title":"Assessment of structure-activity relationships and biased agonism at the Mu opioid receptor of novel synthetic opioids using a novel, stable bio-assay platform","volume":"177","author":"Vasudevan","year":"2020","journal-title":"Biochem. Pharmacol."},{"issue":"1","key":"10.1016\/j.bcp.2021.114805_b0140","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1002\/dta.2906","article-title":"Activation of the mu-opioid receptor by alicyclic fentanyls: changes from high potency full agonists to low potency partial agonists with increasing alicyclic substructure","volume":"13","author":"Astrand","year":"2021","journal-title":"Drug Test. Anal."},{"key":"10.1016\/j.bcp.2021.114805_b0145","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.neuropharm.2019.03.023","article-title":"Opioid-like antinociceptive and locomotor effects of emerging fentanyl-related substances","volume":"151","author":"Varshneya","year":"2019","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.bcp.2021.114805_b0150","doi-asserted-by":"crossref","first-page":"173242","DOI":"10.1016\/j.pbb.2021.173242","article-title":"Fentanyl-related substances elicit antinociception and hyperlocomotion in mice via opioid receptors","volume":"208","author":"Varshneya","year":"2021","journal-title":"Pharmacol. Biochem. Behav."},{"issue":"2","key":"10.1016\/j.bcp.2021.114805_b0155","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/S0022-3565(25)20240-3","article-title":"Mirfentanil: pharmacological profile of a novel fentanyl derivative with opioid and nonopioid effects","volume":"258","author":"France","year":"1991","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"3","key":"10.1016\/j.bcp.2021.114805_b0160","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/BF02245876","article-title":"Pharmacological profile of a potent, efficacious fentanyl derivative in rhesus monkeys","volume":"109","author":"France","year":"1992","journal-title":"Psychopharmacology"},{"issue":"12","key":"10.1016\/j.bcp.2021.114805_b0165","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1021\/jm00132a007","article-title":"4-Phenyl- and 4-heteroaryl-4-anilidopiperidines. A novel class of analgesic and anesthetic agents","volume":"32","author":"Kudzma","year":"1989","journal-title":"J. Med. Chem."},{"issue":"6328","key":"10.1016\/j.bcp.2021.114805_b0170","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1126\/science.aai8636","article-title":"A nontoxic pain killer designed by modeling of pathological receptor conformations","volume":"355","author":"Spahn","year":"2017","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.bcp.2021.114805_b0175","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1021\/acschemneuro.8b00363","article-title":"Synthesis and biological evaluation of fentanyl analogues modified at phenyl groups with alkyls","volume":"10","author":"Qin","year":"2019","journal-title":"ACS Chem. Neurosci."},{"issue":"2","key":"10.1016\/j.bcp.2021.114805_b0180","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1002\/ddr.430220209","article-title":"Evaluation of the morphine reversal actions and antinociceptive activity of a new class of opiate antagonists structurally related to fentanyl","volume":"22","author":"Wynn","year":"1991","journal-title":"Drug Dev. Res."},{"issue":"3","key":"10.1016\/j.bcp.2021.114805_b0185","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1021\/jm00123a028","article-title":"New 4-(heteroanilido)piperidines, structurally related to the pure opioid agonist fentanyl, with agonist and\/or antagonist properties","volume":"32","author":"Bagley","year":"1989","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bcp.2021.114805_b0190","unstructured":"European Monitoring Centre for Drugs and Drug Addiction, Furanylfentanyl. EMCDDA\u2013Europol Joint Report on a new psychoactive substance: N-phenyl-N-[1-(2-phenylethyl) piperidin-4-yl]-furan-2-carboxamide (furanylfentanyl). EMCDDA\u2013Europol Joint Reports, 2017."},{"key":"10.1016\/j.bcp.2021.114805_b0195","unstructured":"World Health Organization Expert Committee on Drug Dependence, FURANYL FENTANYL, World Health Organization Critical Review Reports, Geneva, Switzerland, 2017."},{"key":"10.1016\/j.bcp.2021.114805_b0200","unstructured":"A.J. Krotulski, B.K. Logan, Phenylfentanyl, Toxicology Analytical Reports, The Center for Forensic Science Research & Education, 2018."},{"key":"10.1016\/j.bcp.2021.114805_b0205","unstructured":"Drug Enforcement Administration, Schedules of Controlled Substances: Placement of 10 Specific Fentanyl-Related Substances in Schedule I, Docket No. DEA\u2013476, 2021."},{"key":"10.1016\/j.bcp.2021.114805_b0210","unstructured":"Drug Enforcement Administration, Schedules of Controlled Substances: Placement of Four Specific Fentanyl-Related Substances in Schedule I, Docket No. DEA\u2013806, 2021."},{"issue":"1","key":"10.1016\/j.bcp.2021.114805_b0215","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1021\/acsomega.7b01536","article-title":"LC-MS\/MS-based method for the multiplex detection of 24 fentanyl analogues and metabolites in whole blood at sub ng mL(-1) concentrations","volume":"3","author":"Strayer","year":"2018","journal-title":"ACS Omega"},{"issue":"1","key":"10.1016\/j.bcp.2021.114805_b0220","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11419-017-0371-z","article-title":"Furanylfentanyl: another fentanyl analogue, another hazard for public health","volume":"36","author":"Misailidi","year":"2017","journal-title":"Forensic Toxicol."},{"issue":"43","key":"10.1016\/j.bcp.2021.114805_b0225","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.15585\/mmwr.mm6643e1","article-title":"Deaths Involving Fentanyl, Fentanyl Analogs, and U-47700 - 10 States, July-December 2016","volume":"66","author":"O\u2019Donnell","year":"2017","journal-title":"MMWR Morb. Mortal. Wkly Rep."},{"key":"10.1016\/j.bcp.2021.114805_b0230","doi-asserted-by":"crossref","first-page":"110","DOI":"10.3389\/fpsyt.2017.00110","article-title":"An expanding world of novel psychoactive substances: opioids","volume":"8","author":"Zawilska","year":"2017","journal-title":"Front. Psychiatry"},{"key":"10.1016\/j.bcp.2021.114805_b0235","unstructured":"Committee for the Update of the Guide for the Care and Use of Laboratory Animals, Guide for the Care and Use of Laboratory Animals, Institute for Laboratory Animal Research; Division on Earth and Life Studies; National Research Council of the National Academies (2011)."},{"key":"10.1016\/j.bcp.2021.114805_b0240","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.jneumeth.2017.04.007","article-title":"Light and the laboratory mouse","volume":"300","author":"Peirson","year":"2018","journal-title":"J. Neurosci. Methods"},{"issue":"2","key":"10.1016\/j.bcp.2021.114805_b0245","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1111\/bph.14860","article-title":"Fentanyl depression of respiration: Comparison with heroin and morphine","volume":"177","author":"Hill","year":"2019","journal-title":"Br. J. Pharmacol."},{"issue":"12","key":"10.1016\/j.bcp.2021.114805_b0250","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1111\/bph.14219","article-title":"Oxycodone-induced tolerance to respiratory depression: reversal by ethanol, pregabalin and protein kinase C inhibition","volume":"175","author":"Hill","year":"2018","journal-title":"Br. J. Pharmacol."},{"issue":"13","key":"10.1016\/j.bcp.2021.114805_b0255","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.1111\/bph.14224","article-title":"The novel mu-opioid receptor agonist PZM21 depresses respiration and induces tolerance to antinociception","volume":"175","author":"Hill","year":"2018","journal-title":"Br. J. Pharmacol."},{"issue":"3","key":"10.1016\/j.bcp.2021.114805_b0260","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1038\/npp.2015.201","article-title":"Ethanol reversal of tolerance to the respiratory depressant effects of morphine","volume":"41","author":"Hill","year":"2016","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"10.1016\/j.bcp.2021.114805_b0265","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/S0022-3565(25)25010-8","article-title":"Respiratory effects of morphine in awake unrestrained rats","volume":"237","author":"van den Hoogen","year":"1986","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.bcp.2021.114805_b0270","doi-asserted-by":"crossref","first-page":"107101","DOI":"10.1016\/j.vascn.2021.107101","article-title":"The use of hypercapnic conditions to assess opioid-induced respiratory depression in rats","volume":"111","author":"Crowley","year":"2021","journal-title":"J. Pharmacol. Toxicol. Methods"},{"issue":"2","key":"10.1016\/j.bcp.2021.114805_b0275","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1080\/08958378.2017.1282065","article-title":"Effects of inhaled aerosolized carfentanil on real-time physiological responses in mice: a preliminary evaluation of naloxone","volume":"29","author":"Wong","year":"2017","journal-title":"Inhal. Toxicol."},{"key":"10.1016\/j.bcp.2021.114805_b0280","series-title":"Statistical power analysis for the behavioral sciences","author":"Cohen","year":"1988"},{"issue":"2","key":"10.1016\/j.bcp.2021.114805_b0285","doi-asserted-by":"crossref","first-page":"175","DOI":"10.3758\/BF03193146","article-title":"G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences","volume":"39","author":"Faul","year":"2007","journal-title":"Behav. Res. Methods"},{"issue":"4","key":"10.1016\/j.bcp.2021.114805_b0290","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.3758\/BRM.41.4.1149","article-title":"Statistical power analyses using G*Power 3.1: tests for correlation and regression analyses","volume":"41","author":"Faul","year":"2009","journal-title":"Behav. Res. Methods"},{"issue":"2","key":"10.1016\/j.bcp.2021.114805_b0295","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1097\/00000542-199108000-00009","article-title":"Absorption and bioavailability of oral transmucosal fentanyl citrate","volume":"75","author":"Streisand","year":"1991","journal-title":"Anesthesiology"},{"issue":"1","key":"10.1016\/j.bcp.2021.114805_b0300","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/BF02245094","article-title":"Opioid operant self-administration, analgesia, stimulation and respiratory depression in mu-deficient mice","volume":"117","author":"Elmer","year":"1995","journal-title":"Psychopharmacology"},{"issue":"456","key":"10.1016\/j.bcp.2021.114805_b0305","doi-asserted-by":"crossref","first-page":"eaar3483","DOI":"10.1126\/scitranslmed.aar3483","article-title":"A bifunctional nociceptin and mu opioid receptor agonist is analgesic without opioid side effects in nonhuman primates","volume":"10","author":"Ding","year":"2018","journal-title":"Sci. Transl. Med."},{"issue":"3","key":"10.1016\/j.bcp.2021.114805_b0310","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1124\/jpet.109.156711","article-title":"Nociceptin\/orphanin FQ receptor activation attenuates antinociception induced by mixed nociceptin\/orphanin FQ\/mu-opioid receptor agonists","volume":"331","author":"Khroyan","year":"2009","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"4","key":"10.1016\/j.bcp.2021.114805_b0315","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1111\/j.1476-5381.1977.tb07533.x","article-title":"The animal pharmacology of buprenorphine, an oripavine analgesic agent","volume":"60","author":"Cowan","year":"1977","journal-title":"Br. J. Pharmacol."},{"issue":"2","key":"10.1016\/j.bcp.2021.114805_b0320","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/S0022-3565(24)29586-0","article-title":"Comparison of pharmacological activities of buprenorphine and norbuprenorphine: norbuprenorphine is a potent opioid agonist","volume":"297","author":"Huang","year":"2001","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"11","key":"10.1016\/j.bcp.2021.114805_b0325","doi-asserted-by":"crossref","first-page":"965","DOI":"10.2165\/00003088-200746110-00004","article-title":"Mechanism-based pharmacokinetic-pharmacodynamic modelling of the reversal of buprenorphine-induced respiratory depression by naloxone : a study in healthy volunteers","volume":"46","author":"Yassen","year":"2007","journal-title":"Clin. Pharmacokinet."},{"issue":"2","key":"10.1016\/j.bcp.2021.114805_b0330","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1124\/jpet.106.115972","article-title":"Pharmacokinetic-pharmacodynamic modeling of the respiratory depressant effect of norbuprenorphine in rats","volume":"321","author":"Yassen","year":"2007","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"1","key":"10.1016\/j.bcp.2021.114805_b0335","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1124\/jpet.112.194308","article-title":"Roles of mu-opioid receptors and nociceptin\/orphanin FQ peptide receptors in buprenorphine-induced physiological responses in primates","volume":"343","author":"Cremeans","year":"2012","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"5","key":"10.1016\/j.bcp.2021.114805_b0340","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1038\/clpt.1994.71","article-title":"Clinical pharmacology of buprenorphine: ceiling effects at high doses","volume":"55","author":"Walsh","year":"1994","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.bcp.2021.114805_b0345","unstructured":"S.D. Brandt, Janowsky A. 4-Methoxy-butyryl fentanyl. N-(4-Methoxyphenyl)-N-(1-phenethylpiperidin-4-yl)butyramide, monohydrochloride. Binding and functional activity at delta, kappa and mu opioid receptors. DEA-VA interagency agreement title: \u201cin vitro receptor and transporter assays for abuse liability testing for the DEA by the VA\u201d. March 2016, as cited in: Brandt, S., 2018. Critical Review Report: p-Methoxy-butyrylfentanyl, Expert Committee on Drug Dependence Forty-first Meeting. Geneva, Switzerland, (2018)."},{"issue":"2","key":"10.1016\/j.bcp.2021.114805_b0350","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1124\/jpet.119.258566","article-title":"Noradrenergic mechanisms in fentanyl-mediated rapid death explain failure of naloxone in the opioid crisis","volume":"371","author":"Torralva","year":"2019","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.bcp.2021.114805_b0355","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2021.108974","article-title":"Fentanyl causes naloxone-resistant vocal cord closure: A platform for testing opioid overdose treatments","volume":"227","author":"Miner","year":"2021","journal-title":"Drug Alcohol Depend."},{"issue":"5","key":"10.1016\/j.bcp.2021.114805_b0360","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1097\/00000542-200105000-00021","article-title":"Anesthetic potency and influence of morphine and sevoflurane on respiration in mu-opioid receptor knockout mice","volume":"94","author":"Dahan","year":"2001","journal-title":"Anesthesiology"}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295221004214?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295221004214?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T15:08:44Z","timestamp":1762096124000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295221004214"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":72,"alternative-id":["S0006295221004214"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2021.114805","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Respiratory depressant effects of fentanyl analogs are opioid receptor-mediated","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2021.114805","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"114805"}}